New Delhi: Contract development and manufacturing organization Akums Group said on Thursday that it has entered into a strategic long-term agreement at an estimated value of 200 million euros (Rs 1,760 crore) with an undisclosed global pharma firm for manufacturing and supply of formulations in the European market. Under this collaboration, Akums Group will produce and supply multiple stock-keeping units of oral liquid formulations, which the partner company will market across various European countries, the company said in a statement.
ALSO READ: Exporters Target US Export Market To Tap $25 Billion Potential Amid Tariff Threats On China
"The total value of this agreement is estimated at 200 million euros (Rs 1,760 crore). As part of the agreement, Akums Group will receive an upfront payment of 100 million euros (Rs 880 crore) for product development and site approval from European authorities," it added.
Akums signs €200 million deal to supply oral liquid formulations.
While commenting on the development, Akums Managing Director Sanjeev Jain said, "This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally." The commercial supply of these products is expected to begin in 2027 and will continue to be supplied till 2032, the company said.
ALSO READ: Rebranding Amid Legal Hurdles: How Sairah Jewels Became Assam’s 1st AR Jewellery Brand?
As part of this initiative, Akums Group will initiate the European approval process for its oral liquid manufacturing facility, leveraging this approval to produce the contracted products, it added. "The site and product dossier approvals are expected to be received by the end of 2026," Akums said, adding it already operates two European-approved facilities for injectables and oral solids.
FIRST Business Portal addressing the potential of business capability of North East Region.
